Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)
Status:
Completed
Trial end date:
2014-05-05
Target enrollment:
Participant gender:
Summary
This adaptive design study will evaluate the safety, pharmacokinetics, and effect on
hepatitis C virus (HCV) RNA levels of multiple doses of MK-8876 in participants with HCV
infection. The study will consist of 4 parts evaluating participants infected with specific
hepatitis C virus genotypes and up to 10 panels allowing for additional participants to
enroll in each panel as specified in the study analysis. The hypothesis evaluated in the
study is that a ≥2.5 log IU/mL reduction in HCV RNA from Baseline will accompany multiple
dose administration of MK-8876 in participants with HCV infection.